Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Genetic defect makes malignant smooth muscle tumors vulnerable

No. 01c2 | 10/01/2018 | by Koh

A research team under the leadership of scientists from the German Cancer Research Center (DKFZ) and the National Center for Tumor Diseases (NCT) Heidelberg have conducted the first comprehensive analysis of the genome of malignant smooth muscle tumors. In a high percentage of tumors, they discovered a weak spot in the genome of the cancer cells that may serve as a therapy target in the future.

Leiomyosarcoma is a cancer of the smooth muscles
© Polarlys / Wikipedia

Leiomyosarcoma is a type of cancer of the smooth muscles that can arise almost anywhere in the body. Common places are the uterus, the abdomen or the muscles of the blood vessels. Even the tiny muscles that make our hair stand on end can be affected.

Like most other types of sarcoma, leiomyosarcomas respond very poorly to chemotherapy. In many cases, surgery and radiotherapy are the only effective treatment options. "Unfortunately, many tumors recur despite radical surgery or have already spread in the body," said Stefan Fröhling, an oncologist who works at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ), the National Center for Tumor Diseases (NCT) Heidelberg and Heidelberg University Hospital.

Leiomyosarcoma is a very rare type of cancer. Only about 150 to 200 cases are diagnosed each year in Germany. Therefore, little is known to date about its molecular causes. In collaboration with other partner sites of the German Cancer Consortium (DKTK) as well as partners in Mannheim and Rotterdam, Fröhling and his colleagues have now been the first to study the genetic causes of leiomyosarcoma in a comprehensive analysis of tumor samples from 49 patients. The researchers sequenced the tumor genomes and analyzed the genes that showed particular activity. "An analysis of this kind would not have been possible at a single hospital," Fröhling said. "One of our goals was to find specific alterations that can be used to attack the cancer cells using targeted drugs."

The researchers found a state of complete chaos in the genome of leiomyosarcoma. In many cases, large parts of the genome were missing or were present in multiple copies. In some cases, the whole genome had doubled or even tripled. In particular, the investigators noticed that the two most important cancer brakes, tumor suppressor genes TP53 and RB1, were absent in extremely many cases. In over 90 percent of the samples under investigation, both of their gene copies had been destroyed.

The analysis also revealed how the tumor cells acquire immortality. In over 75 percent of the cases studied, the cancer cells had found different ways of lengthening their telomeres. In healthy cells, the length of these structures on the ends of chromosomes limits the number of possible divisions.

The scientists also made an encouraging discovery: In most tumors, they found evidence suggesting that an important DNA repair system known as homologous recombination had been disrupted. As a result, the cancer cells become sensitive to substances that destroy DNA such as certain chemotherapy agents. Another tactic for cancer cells with this type of mutation is to use substances called PARP inhibitors to disable also the other key cellular DNA repair system. "Then the cancer cells die from their genomic defects," explained Claudia Scholl from DKFZ, who led the investigation jointly with Fröhling.

The researchers have already been able to confirm this theory in leiomyosarcoma cells in the Petri dish. "First clinical trials will examine whether this approach is effective in bone sarcoma," Scholl said. "We have found a starting point which we might be able to use to better help people with leiomyosarcoma in the future," the scientist said.

Priya Chudasama, Sadaf S. Mughal, Mathijs A. Sanders, Daniel Hübschmann, Inn Chung, Katharina I. Deeg, Siao-Han Wong, Sophie Rabe, Mario Hlevnjak, Marc Zapatka, Aurélie Ernst, Kortine Kleinheinz, Matthias Schlesner, Lina Sieverling, Barbara Klink, Evelin Schröck, Remco M. Hoogenboezem, Bernd Kasper, Christoph E. Heilig, Gerlinde, Egerer, Stephan Wolf, Christof von Kalle, Roland Eils, Albrecht Stenzinger, Wilko Weichert, Hanno Glimm, Stefan Gröschel, Hans-Georg Kopp, Georg Omlor, Burkhard Lehner, Sebastian Bauer, Simon Schimmack, Alexis Ulrich, Gunhild Mechtersheimer, Karsten Rippe, Benedikt Brors, Barbara Hutter, Marcus Renner, Peter Hohenberger, Claudia Scholl & Stefan Fröhling: Integrative genomic and transcriptomic analysis of leiomyosarcoma
Nature Communications 2018, DOI: 10.1038/s41467-017-02602-0


With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.

To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:

  • National Center for Tumor Diseases (NCT, 6 sites)
  • German Cancer Consortium (DKTK, 8 sites)
  • Hopp Children's Cancer Center (KiTZ) Heidelberg
  • Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ
  • DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
  • National Cancer Prevention Center (jointly with German Cancer Aid)
The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.


Subscribe to our RSS-Feed.

to top
powered by webEdition CMS